Press Releases Keyword Search Year: 202120202019201820172016201520142013 Aug 30, 2021 Summary ToggleAgios To Present at September Investor Conferences Aug 17, 2021 Summary ToggleAgios Announces FDA Acceptance and Priority Review of New Drug Application for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency Jul 29, 2021 Summary ToggleAgios Reports Business Highlights and Second Quarter 2021 Financial Results Jul 15, 2021 Summary ToggleAgios to Webcast Conference Call of Second Quarter 2021 Financial Results on July 29, 2021 Jun 28, 2021 Summary ToggleAgios Submits Marketing Authorisation Application to European Medicines Agency for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency Jun 22, 2021 Summary ToggleAgios Launches myAgios® Patient Support Services for Pyruvate Kinase Deficiency Jun 21, 2021 Summary ToggleAgios Submits New Drug Application to FDA for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency Jun 11, 2021 Summary ToggleAgios Announces Updated Data from ACTIVATE and ACTIVATE-T Phase 3 Studies of Mitapivat in Pyruvate Kinase (PK) Deficiency at the European Hematology Association Virtual Congress Jun 11, 2021 Summary ToggleAgios Presents Positive Results from Phase 2 Study of Mitapivat in Non-transfusion-dependent α- and β-Thalassemia at the European Hematology Association Virtual Congress May 12, 2021 Summary ToggleAgios to Present Updated Data from Clinical Trials of Mitapivat in Pyruvate Kinase Deficiency and Thalassemia in Oral Presentations at the European Hematology Association Annual Congress Apr 29, 2021 Summary ToggleAgios Reports Business Highlights and First Quarter 2021 Financial Results Apr 15, 2021 Summary ToggleAgios to Webcast Conference Call of First Quarter 2021 Financial Results on April 29, 2021 Apr 1, 2021 Summary ToggleAgios Announces Closing of Oncology Business Sale to Servier Mar 25, 2021 Summary ToggleAgios Shareholders Approve Sale of Oncology Business to Servier Mar 18, 2021 Summary ToggleAgios Sponsors Program Promoting Health Literacy for Patients with Sickle Cell Disease Mar 1, 2021 Summary ToggleAgios Submits Supplemental New Drug Application to FDA for TIBSOVO® (ivosidenib tablets) for Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma Feb 26, 2021 Summary ToggleAgios Recognizes 14th Annual Rare Disease Day and Raises Awareness of Unmet Needs in Rare Hemolytic Anemias Feb 25, 2021 Summary ToggleAgios Reports Fourth Quarter and Full Year 2020 Financial Results Feb 23, 2021 Summary ToggleAgios to Present at March Investor Conferences Feb 11, 2021 Summary ToggleAgios to Webcast Conference Call of Fourth Quarter and Year End 2020 Financial Results on February 25, 2021 Jan 26, 2021 Summary ToggleAgios Announces Phase 3 ACTIVATE-T Trial of Mitapivat Achieved Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Regularly Transfused Jan 17, 2021 Summary ToggleAgios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma Jan 11, 2021 Summary ToggleAgios Highlights 2021 Milestones to Accelerate and Expand Its Genetically Defined Disease Portfolio and Drive Near- and Long-Term Value Creation Jan 5, 2021 Summary ToggleAgios to Present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 Dec 21, 2020 Summary ToggleAgios to Focus on Developing and Commercializing Innovative Treatments for Genetically Defined Diseases and Sell Its Oncology Business to Servier for Up to $2 Billion Plus Royalties Dec 7, 2020 Summary ToggleAgios Announces Updated Data from Phase 1 Study of Mitapivat, First-in-Class PKR Activator, in Sickle Cell Disease Dec 1, 2020 Summary ToggleAgios Announces the Phase 3 ACTIVATE Trial of Mitapivat Achieved Its Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Not Regularly Transfused Nov 30, 2020 Summary ToggleAgios Launches Anemia ID, a No-Cost Genetic Testing Program for Hereditary Anemias Nov 25, 2020 Summary ToggleAgios to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020 Nov 12, 2020 Summary ToggleAgios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Sickle Cell Disease Nov 5, 2020 Summary ToggleAgios Reports Business Highlights and Third Quarter 2020 Financial Results Nov 4, 2020 Summary ToggleAgios to Present Broad Set of Clinical and Translational Data for Oncology and Rare Genetic Disease Programs at the Virtual 2020 ASH Annual Meeting Oct 29, 2020 Summary ToggleAgios to Host a Webinar on its Pyruvate Kinase-R (PKR) Activation Clinical Programs and Commercial Outlook on Thursday, November 19, 2020 Oct 22, 2020 Summary ToggleAgios to Webcast Conference Call of Third Quarter 2020 Financial Results on November 5, 2020 Oct 16, 2020 Summary ToggleAgios Announces Withdrawal of European Marketing Authorization Application for TIBSOVO® as a Treatment for Relapsed or Refractory IDH1-mutant Acute Myeloid Leukemia Sep 21, 2020 Summary ToggleAgios Announces Final Overall Survival Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Previously Treated IDH1-Mutant Cholangiocarcinoma Patients Sep 8, 2020 Summary ToggleAgios Appoints Jonathan Biller as Chief Financial Officer, Head of Legal and Corporate Affairs Aug 27, 2020 Summary ToggleAgios to Present at the Citi 15th Annual BioPharma Virtual Conference on Wednesday, September 9, 2020 Aug 6, 2020 Summary ToggleAgios to Present at the Virtual Canaccord 40th Annual Growth Conference on Thursday, August 13, 2020 Jul 30, 2020 Summary ToggleAgios Reports Business Highlights and Second Quarter 2020 Financial Results Jul 16, 2020 Summary ToggleAgios to Webcast Conference Call of Second Quarter 2020 Financial Results on July 30, 2020 Jun 17, 2020 Summary ToggleAgios to Present at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference on Tuesday, June 23, 2020 Jun 12, 2020 Summary ToggleAgios and Royalty Pharma Announce $255 Million Purchase Agreement for IDHIFA® Royalty Jun 12, 2020 Summary ToggleAgios Announces Clinical Proof-of-Concept Has Been Established in Phase 1 Study of Mitapivat, First-in Class PKR Activator, in Sickle Cell Disease Jun 12, 2020 Summary ToggleAgios First-in Class PKR Activator Mitapivat Demonstrates Sustained Hemoglobin Responses in Non-transfusion-dependent α- and β-Thalassemia in Phase 2 Study Pagination Current page 1 Page 2 Page 3 Page 4 … Next page Next Last page Last